Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Verbeke, Len, Farre, Ricard, Trebicka, Jonel, Komuta, Mina, Roskams, Tania, Klein, Sabine, Elst, Ingrid Vander, Windmolders, Petra +3 more·2014·Hepatology
DOI 10.1002/hep.26939

Cited by (259)

Items 201–259 of 259

  1. Novel Therapies in Primary Biliary Cholangitis
    Keri-Ann Buchanan-Peart, Cynthia Levy · 2022 · Clinics in Liver Disease
  2. Breaking Bad– the two sides of gut microbiota in portal hypertension
    Gautam Mehta, Rajeshwar P. Mookerjee · 2014 · Liver International
  3. NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
    Stefania Grimaudo, Paola Dongiovanni, Jussi Pihlajamäki, Mohammed Eslam, Hannele Yki‐Järvinen, Rosaria Maria Pipitone, Guido Baselli, Calogero Cammà, Vito Di Marco, Marco Enea et al. · 2021 · Liver International
  4. Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
    Shengying Qian, Xiaolin Wang, Yingfen Chen, Qiuhong Zai, Yong He · 2024 · Seminars in Liver Disease
  5. Tailoring obeticholic acid activity by iridium(III) complex conjugation to develop a farnesoid X receptor probe
    Dou Niu, Xiaolei Wu, Yuxin Zhang, Xueliang Wang, Daniel Shiu‐Hin Chan, Shaozhen Jing, Chun‐Yuen Wong, Wanhe Wang, Chung‐Hang Leung · 2024 · Journal of Advanced Research
  6. Bile acids as gatekeepers: Orchestrating gut-liver axis for metabolic and immune balance
    Qiang Chen, Xin LIU, Zi-Hao Jiang · 2026 · Hepatobiliary & pancreatic diseases international
  7. Obeticholic acid for the treatment of primary biliary cirrhosis
    Kidist K. Yimam, Christopher L. Bowlus · 2014 · Expert Opinion on Orphan Drugs
  8. Evolving insights in the pathophysiology of complications of cirrhosis: The farnesoid X receptor (FXR) to the rescue?
    W. Laleman, J. Trebicka, L. Verbeke · 2016 · Hepatology
  9. Current and investigational drugs in early clinical development for portal hypertension
    Sasan Sakiani, Theo Heller, Christopher Koh · 2022 · Frontiers in Medicine
  10. The relationship between gut microbiota and spontaneous bacterial peritonitis in patients with liver cirrhosis - a literature review
    Roxana-Emanuela Popoiag, Anca Pantea Stoian, Adrian Paul Suceveanu, Andra‐Iulia Suceveanu, Laura Mazilu, Irinel Raluca Parepa, Laura Serban, Mihai Păunică, Cătălina Motofei, Carmen Georgeta Fierbinteanu-Braticevici · 2019 · Journal of Mind and Medical Sciences
  11. Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart
    Calen A. Steiner, Peter Higgins · 2018 · Springer eBooks
  12. Portal Hypertension in NASH: Is It Different from Other Aetiologies?
    Sven Francque, Wilhelmus Josephus Kwanten, Denise van der Graaff · 2019 · Current Hepatology Reports
  13. The expanding role of the bile acid receptor farnesoid X in the intestine and its potential clinical implications
    Laurens Joseph Ceulemans, Emilio Canovai, Len Verbeke, Jacques Pirenne, Ricard Farré · 2016 · Acta chirurgica Belgica
  14. Dihydroartemisinin: A Promising Therapeutic Agent Against the Hepatitis-to-Hepatocellular Carcinoma Cascade
    Ting-Yao Wang, Wei Jiang, Ji-Qiang Li, Jia Ma, Yuan-Hao Zhang, Ji-Jun Zheng, Jie Chen, Yue-Qiang Wen, Xiao Ma, Jin-Hao Zeng · 2025 · Drug Design, Development and Therapy
  15. Role of Intestinal Barrier Disruption to Acute-on-Chronic Liver Failure
    Julian Pohl, Dimitrios Aretakis, Frank Tacke, Cornelius Engelmann, Michael J. Sigal · 2025 · Seminars in Liver Disease
  16. The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
    Xue Wang, Chunyou Ning, Xingyi Cheng, Zhengzhong Wu, Dongbo Wu, Xuemei Ding, Cunxiang Ju, Zhihang Zhou, Lingfeng Wan, Wei Zhao et al. · 2024 · Animal Models and Experimental Medicine
  17. Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis
    Jan Görtzen, Robert Schierwagen, Jeanette Bierwolf, S. Klein, Frank Erhard Uschner, P. van der Ven, Dieter O. Fürst, Christian P. Strassburg, Wim Laleman, Joerg‐Matthias Pollok et al. · 2016 · Journal of Hepatology
  18. Glytan decreases portal pressureviamesentery vasoconstriction in portal hypertensive rats
    Qing‐Hong Du · 2014 · World Journal of Gastroenterology
  19. Novel Targets and Drug Development in Portal Hypertension
    Robert Schierwagen, Sabine Klein, Frank Erhard Uschner, Jonel Trebicka · 2019 · Current Hepatology Reports
  20. Obeticholic acid: A new light in the shadows treating portal hypertension?
    Jordi Gracia‐Sancho, Virginia Hernández–Gea, Juan Carlos García‐Pagán · 2014 · Hepatology
  21. Fibrogenic Gene Signature as Early Prediction for the Efficacy of Pharmacological Interventions for MASH ‐Associated Fibrosis
    José A. Inia, Martine C. Morrison, Arianne van Koppen, Eveline Gart, Martien P. M. Caspers, Aswin L. Menke, Nicole Worms, Robert Kleemann, Lars Verschuren, J. Wouter Jukema et al. · 2025 · The FASEB Journal
  22. Stability Indicating RP-HPLC Method Development and Validation for the Quantification of Obeticholic Acid in Bulk and its Pharmaceutical Dosage Form
    R. Kiran Joythi, Kothapalli Bannoth Chandrasekhar, Balakrishnan M Balakrishnan, Badithala Siva Sai Kiran · 2020 · Indian Journal of Pharmaceutical Education and Research
  23. Novel Approaches to Reducing the Risk of Variceal Hemorrhage
    Frederik Nevens · 2017 · Digestive Diseases
  24. Drug Discovery in Tissue Fibrosis
    S. Pinto, Maarten Hoek, Yonghong Huang, Philippe Costet, L. Ma, Jason E. Imbriglio · 2017 · Elsevier eBooks
  25. Intestinal mucus and gut-vascular barrier: FxR-modulated entry sites for pathological bacterial translocation in liver cirrhosis
    Marcel Sorribas, M. O. Jakob, B. Yilmaz, H. Li, D. Stutz, Y. Noser, Andrea De Gottardi, Sheida Moghadamrad, M. Hassan, A. Albillos et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  26. Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
    Elisabeth Tatscher, Samy Mady, Peter Fickert · 2025 · Seminars in Liver Disease
  27. A Novel FXR-Targeted DUBTAC and Its Applications in Cholestasis Therapy
    Ming Cui, Bin Tang, Tingting Yao, Wenbin Shao, Qiuling Zheng, Huiyong Sun, Haiping Hao, Hao Wang, Xiaowei Xu · 2026 · Journal of Medicinal Chemistry
  28. Liver sinusoidal endothelial cells in liver diseases and hepatocellular carcinoma: molecular mechanisms, physiology, and therapies
    Meng-Yao Yan, Yi-Min Cui, Qian Xiang · 2026 · Molecular Biomedicine
  29. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension
    Jiyao Sheng, Zifan Meng, Qiao Li, Yongsheng Yang · 2023 · Hepatobiliary & pancreatic diseases international
  30. Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
    Anabel Fernández‐Iglesias, Jordi Gracia‐Sancho · 2024 · Elsevier eBooks
  31. The Gut Microbiome and Cirrhosis: Basic Aspects
    Reiner Wiest · 2015 · Springer eBooks
  32. Work in Progress
    Gwilym James Webb, Gideon Morris Hirschfield · 2018 · Clinics in Liver Disease
  33. Facial synthesis of key intermediate of obeticholic acid via Pd-catalyzed Kumada-Tamao-Corriu cross-coupling reaction
    Xiangjie Di, Jie Han, Sheng Zou, Xia Wei, Qingfei Huang, Jin Zhu, Yuanhua Wang, Liu Zhong, Qiwei Wang · 2020 · Steroids
  34. A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
    Robert Schierwagen, Sabine Klein, Jonel Trebicka · 2020 · Cellular and Molecular Gastroenterology and Hepatology
  35. Investigational drugs in early clinical development for portal hypertension
    Susana Gomes Rodrigues, Yuly Paulin Mendoza, Jaime Bosch · 2022 · Expert Opinion on Investigational Drugs
  36. RP-HPLC analytical method development and validation of obeticholic acid in bulk and marketed formulation
    Pawan S. Avhad, Revathi A. Gupta · 2022 · International Journal of Health Sciences
  37. Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis)
    Palak Jitendrakumar Trivedi, Gideon Morris Hirschfield · 2019 · Wiley eBooks
  38. Hepatic Circulation
    Thomas Greuter, Vijay H. Shah · 2018 · Encyclopedia of Gastroenterology
  39. Cirrhotic Portal Hypertension: New Insights in an Old Syndrome
    Priscila Pollo‐Flores, Mônica Soldan, Guilherme Rezende · 2015 · Saúde e Pesquisa
  40. Potential Antifibrotic Therapies: Approaching the Bedside: Proof-of-Concept Studies (Part 1)
    Wim Laleman · 2015 · Springer eBooks
  41. Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis
    Robert Schierwagen, Frank Erhard Uschner, Sabine Klein, Jonel Trebicka · 2016 · Current Hepatology Reports
  42. Targeting liver inflammatory myeloid cells with immunomodulatory liposomes improves nonalcoholic steatohepatitis in mice
    Muralidhara Rao Maradana · 2016 · The University of Queensland
  43. Therapeutic Monitoring of Portal Pressure Lowering Drugs Using Liver Stiffness
    Omar Elshaarawy, Felix Piecha, Sebastian Mueller · 2020 · Springer eBooks
  44. Pharmacological Options for NASH
    Christiane Stern, Vlad Ratziu · 2020 · Springer eBooks
  45. Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms
    Marek Rác, Ľubomír Skladaný · 2018 · Vnitřní lékařství
  46. Brief Review of Portal Hypertension Related Complications
    Achyut Bikram Hamal · 2021 · IntechOpen eBooks
  47. Neue Entwicklungen in der Diagnostik und Therapie der metabolisch assoziierten, nicht-alkoholischen Fettlebererkrankung
    Bandik Föh, Friedhelm Sayk, Jens Uwe Marquardt · 2021 · Adipositas - Ursachen Folgeerkrankungen Therapie
  48. Postoperative liver (dys)function
    Kim M.C. van Mierlo · 2022
  49. Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease
    Hitoshi Yoshiji, Tadashi Namisaki, Kosuke Kaji, Sven Francque · 2022 · Springer eBooks
  50. Peripheral vasculature in portal hypertension
    Seong Hee Kang, Soon Koo Baik · 2023 · Elsevier eBooks
  51. The liver sinusoid in chronic liver disease: NAFLD and NASH
    Wilhelmus Josephus Kwanten, Sven Francque · 2024 · Elsevier eBooks
  52. Cirrhose métabolique : une entité en plein essor
    Vlad Ratziu · 2024 · Bulletin de l Académie Nationale de Médecine
  53. Pathophysiology of portal hypertension in liver cirrhosis
    Mauro Bernardi, Giacomo Zaccherini · 2025 · Elsevier eBooks
  54. New Approaches to Alcohol-Associated Hepatitis
    Rohit Wagh, Saggere Muralikrishna Shasthry, Shiv Kumar Sarin · 2025 · Clinics in Liver Disease
  55. Genomics link obesity and type 2 diabetes to Alzheimer’s disease to unveil novel biological insights
    César Cunha, Mario García‐Ureña, Raquel Martínez, María J Romero-Lado, María Victoria Fernández, Ole A. Andreassen, Rebecca Sims, Magda Tsolaki, Kristel Sleegers, Mikko O. Hiltunen et al. · 2026 · medRxiv
  56. Role of autophagy in liver sinusoidal endothelial cells on nonalcoholic steatohepatitis
    Adel Hammoutène · 2018 · theses.fr (ABES)
  57. Nouveaux aspects dans la prise en charge de la cirrhose
    Delphine Weil · 2019
  58. Prise en charge chirurgicale de l’obèse et de l’obèse morbide : conséquences sur la stéatopathie métabolique et sur l’accès à la transplantation hépatique
    Guillaume Lassailly · 2020 · theses.fr (ABES)
  59. BindingDB Entry 50008196: 7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.
    BindingDB · 2021 · UC San Diego